Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics has raised approximately $2.2 million via a non-renounceable entitlement offer, providing funding to advance its HMBD-002 program toward a planned phase II clinical trial in the second half of 2026 and for working capital. The offer, which included accompanying unlisted options, saw participation from existing shareholders and new sophisticated and institutional investors, underscoring continued capital markets support for the company’s oncology pipeline.
During the quarter, Percheron secured acceptance of HMBD-002-related abstracts at two premier cancer conferences, AACR and ASCO, highlighting positive phase I safety and tolerability data and upcoming preclinical results from its collaboration with QIMR Berghofer. Management is finalising trial design, initiating manufacture of new drug substance by licensor Hummingbird Bioscience, and selecting a contract research organisation, positioning the company for a key value-inflecting clinical milestone and increased scientific and investor visibility.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company developing novel therapies for oncology and rare diseases. Listed on the ASX, FSE and US OTC markets, the company focuses on advancing its lead asset HMBD-002 through clinical development, targeting patients with advanced cancers and aiming to build a position in immuno-oncology.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.61M
Learn more about PER stock on TipRanks’ Stock Analysis page.